Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 28;13(12):e072484.
doi: 10.1136/bmjopen-2023-072484.

Efficacy of cell-based immunotherapies on patients with glioma: an umbrella review of systematic reviews and meta-analysis protocol

Mehdi Nikoobakht #  1   2 , Parisa Shamshiripour #  3   4   5 , Seyed Mostafa Mostafavi Zadeh #  6   7 , Mehrana Rahnama  8 , Fahime Hajiahmadi  9 , Aghdas Ramezani  4 , Vahideh Farzam Rad  4   10 , Elaheh Nazari  10 , Ali-Reza Moradi  4   10 , Mahzad Akbarpour  11 , Davoud Ahmadvand  12
Affiliations

Efficacy of cell-based immunotherapies on patients with glioma: an umbrella review of systematic reviews and meta-analysis protocol

Mehdi Nikoobakht et al. BMJ Open. .

Abstract

Introduction: Glial brain tumours are highly mortal and are noted as major neurosurgical challenges due to frequent recurrence or progression. Despite standard-of-care treatment for gliomas, the prognosis of patients with higher-grade glial tumours is still poor, and hence empowering antitumour immunity against glioma is a potential future oncological prospect. This review is designed to improve our understanding of the efficacy of cell-based immunotherapies for glioma.

Methods and analysis: This systematic review will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive search of main electronic databases: PubMed/MEDLINE, Scopus, ISI Web of Science EMBASE and ProQuest will be done on original articles, followed by a manual review of review articles. Only records in English and only clinical trials will be encountered for full-text review. All the appropriate studies that encountered the inclusion criteria will be screened, selected and then will undergo data extraction step by two independent authors. For meta-analyses, data heterogeneity for each parameter will be first evaluated by Cochran's Q and I2 statistics. In case of possible heterogeneity, a random-effects meta-analysis will be performed and for homogenous data, fixed-effects models will be selected for reporting the results of the proportional meta-analysis. Bias risk will be assessed through Begg's and Egger's tests and will also be visualised by Funnel plots.

Ethics and dissemination: As this study will be a systematic review without human participants' involvement, no ethical registration is required and meta-analysis will be presented at a peer-reviewed journal.

Prospero registration number: CRD42022373297.

Keywords: Neurobiology; Neurological oncology; Neurology; ONCOLOGY.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
A schema of different cell-based immunotherapy strategies to combat glioma growth.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ostrom QT, Bauchet L, Davis FG, et al. . “The epidemiology of glioma in adults: a “state of the science” review”. Neuro Oncol 2014;16:896–913. 10.1093/neuonc/nou087 - DOI - PMC - PubMed
    1. Nabors LB, Portnow J, Ahluwalia M, et al. . Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020;18:1537–70. 10.6004/jnccn.2020.0052 - DOI - PubMed
    1. Hinshaw DC, Shevde LA. The tumor Microenvironment Innately modulates cancer progression. Cancer Res 2019;79:4557–66. 10.1158/0008-5472.CAN-18-3962 - DOI - PMC - PubMed
    1. Artene S-A, Turcu-Stiolica A, Ciurea ME, et al. . Comparative effect of Immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials. Sci Rep 2018;8:11800. 10.1038/s41598-018-30296-x - DOI - PMC - PubMed
    1. Ogbomo H, Cinatl J, Mody CH, et al. . Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy. Trends Mol Med 2011;17:433–41. 10.1016/j.molmed.2011.03.004 - DOI - PubMed
-